TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Dyne Therapeutics ( (DYN) ) is now available.
On October 1, 2025, Dyne Therapeutics, Inc. announced the election of Brian Posner as a Class III director to its Board of Directors. Mr. Posner, deemed an independent director under Nasdaq rules, will serve until the 2026 Annual Meeting of Stockholders. He received stock options and annual cash compensation as part of the company’s non-employee director compensation program. His election is not based on any arrangement or understanding with other persons, and he has no family ties with the company’s directors or executive officers.
The most recent analyst rating on (DYN) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Dyne Therapeutics stock, see the DYN Stock Forecast page.
Spark’s Take on DYN Stock
According to Spark, TipRanks’ AI Analyst, DYN is a Neutral.
Dyne Therapeutics’ stock score reflects its current financial health as a pre-revenue biotech, burdened by losses but supported by a strong balance sheet and recent strategic leadership changes. Technical indicators suggest bearish trends, yet the potential for future breakthroughs could alter its trajectory.
To see Spark’s full report on DYN stock, click here.
More about Dyne Therapeutics
Average Trading Volume: 2,784,255
Technical Sentiment Signal: Sell
Current Market Cap: $1.78B
For a thorough assessment of DYN stock, go to TipRanks’ Stock Analysis page.